77856-51-0Relevant academic research and scientific papers
PCSK9 ANTAGONIST COMPOUNDS
-
Page/Page column 159; 161, (2021/03/05)
Disclosed are compounds of Formula (A), or a pharmaceutically acceptable salt thereof: where A, X, R1, and R2 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula (I) or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
Total synthesis of (+)-blasticidin S
Ichikawa, Yoshiyasu,Hirata, Keiko,Ohayashi, Masayoshi,Isobe, Minoru
, p. 3241 - 3251 (2007/10/03)
The first total synthesis of the peptidyl nucleoside antibiotic, blasticidin S (1), has been achieved by the coupling reaction of cytosinine (3) and blastidic acid (2). A key step in the synthesis of cytosinine (3) is the sigma-tropic rearrangement of all
&β-Amino Acid Isomers of a Natural Substrate of the Enzyme &γ-Glutamyl-amino Acid Cyclotransferase. Synthesis of (3S)-3-Aminoglutaryl-(S)-alanine and (3R)-3-Aminoglutaryl-(S)-alanine
Crossley, Maxwell J.,Fisher, Megan L.,Potter, Jeffrey J.,Kuchel, Philip W.,York, Michael J.
, p. 2363 - 2369 (2007/10/02)
(3S)-3-Aminoglutaryl-(S)-alanine (8) and (3R)-3-aminoglutaryl-(S)-alanine (14), β-amino acid isomers of the dipeptide γ-glutamyl-(S)-alanine, a natural substrate of the enzyme γ-glutamyl-amino acid cyclotransferase, have been synthesized by two different
